Privia Health Q2 Revenue Jumps 21%, Raises Full-Year Guidance
PRVA sits 26% above its 52-week low of $19.08.
Summary
Privia Health delivered a strong Q2, with revenue up 21.4% to $632.6M, beating estimates, and operating income surging 253% to $11.8M. Adjusted EBITDA grew 29% to $37.4M, driven by a 19% increase in value-based care attributed lives to 1.65M. Management raised full-year guidance across key metrics, now expecting attributed lives of 1.625-1.65M and practice collections at the high end of the prior range. The results show accelerating momentum in the provider enablement platform, with care margin and platform contribution both expanding. This follows a Q1 that also beat expectations, suggesting sustained execution. The raised outlook signals confidence in the second half, though the stock's reaction will hinge on whether the market had already priced in this strength.
At the time of this announcement, PRVA was trading at $24.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3B. The 52-week trading range was $19.08 to $28.82. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.